Myung In Pharmaceutical LTD. (KRX:317450)
South Korea flag South Korea · Delayed Price · Currency is KRW
56,900
+600 (1.07%)
At close: Apr 8, 2026

KRX:317450 Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
287,254269,435242,338225,828209,250
Other Revenue
-0---0-0
287,254269,435242,338225,828209,250
Revenue Growth (YoY)
6.61%11.18%7.31%7.92%11.40%
Cost of Revenue
113,269100,55688,41382,28070,954
Gross Profit
173,985168,879153,925143,549138,297
Selling, General & Admin
71,55367,80062,24957,22757,643
Research & Development
5,1523,6844,0374,7492,448
Amortization of Goodwill & Intangibles
1.321.150.981.251.53
Other Operating Expenses
1,6831,5881,4853,5641,326
Operating Expenses
81,48776,12470,30667,64664,091
Operating Income
92,49892,75483,61875,90374,206
Interest Expense
-235.34-322.65-333.54-106.64-133.33
Interest & Investment Income
9,2158,6216,2182,916835.94
Currency Exchange Gain (Loss)
435.195,4901,2042,6874,063
Other Non Operating Income (Expenses)
185.13-9,548527.79406.58797.02
EBT Excluding Unusual Items
102,09996,99491,23581,80679,768
Gain (Loss) on Sale of Investments
--8,310826.42--
Gain (Loss) on Sale of Assets
20.99-609.54-0.3210.76.39
Pretax Income
102,12088,07592,06181,81779,775
Income Tax Expense
20,68419,40417,55024,38320,024
Net Income
81,43568,67174,51257,43459,750
Net Income to Common
81,43568,67174,51257,43459,750
Net Income Growth
18.59%-7.84%29.73%-3.88%31.38%
Shares Outstanding (Basic)
1211111111
Shares Outstanding (Diluted)
1211111111
Shares Change (YoY)
8.23%0.01%---
EPS (Basic)
6718.006131.006652.825128.045334.82
EPS (Diluted)
6718.006131.006652.825128.045334.82
EPS Growth
9.57%-7.84%29.73%-3.88%31.38%
Free Cash Flow
51,52272,78371,42857,64363,407
Free Cash Flow Per Share
4250.336498.196377.485146.685661.37
Dividend Per Share
--2000.0001000.0001250.000
Dividend Growth
--100.00%-20.00%-28.57%
Gross Margin
60.57%62.68%63.52%63.57%66.09%
Operating Margin
32.20%34.43%34.51%33.61%35.46%
Profit Margin
28.35%25.49%30.75%25.43%28.55%
Free Cash Flow Margin
17.94%27.01%29.47%25.52%30.30%
EBITDA
103,439105,21795,05887,23885,824
EBITDA Margin
36.01%39.05%39.23%38.63%41.02%
D&A For EBITDA
10,94012,46311,44011,33611,619
EBIT
92,49892,75483,61875,90374,206
EBIT Margin
32.20%34.43%34.51%33.61%35.46%
Effective Tax Rate
20.26%22.03%19.06%29.80%25.10%
Advertising Expenses
28,66231,18627,86125,26027,110
Source: S&P Global Market Intelligence. Standard template. Financial Sources.